The estimated Net Worth of John R Barr is at least $260 Tisíc dollars as of 10 March 2021. Mr. Barr owns over 10,000 units of Apollo Endosurgery Inc stock worth over $259,700 and over the last 5 years he sold APEN stock worth over $0. In addition, he makes $0 as Independent Director at Apollo Endosurgery Inc.
John has made over 1 trades of the Apollo Endosurgery Inc stock since 2021, according to the Form 4 filled with the SEC. Most recently he bought 10,000 units of APEN stock worth $58,900 on 10 March 2021.
The largest trade he's ever made was buying 10,000 units of Apollo Endosurgery Inc stock on 10 March 2021 worth over $58,900. On average, John trades about 1,667 units every 0 days since 2019. As of 10 March 2021 he still owns at least 25,970 units of Apollo Endosurgery Inc stock.
You can see the complete history of Mr. Barr stock trades at the bottom of the page.
John R. Barr serves as Independent Director of the Company. Since March 2019, Mr. Barr has served as a member of our Board. Since January 2018, Mr. Barr has served as an Operating Partner for Altamont Capital Partners, a private equity firm. From October 2014 through August 2017, Mr. Barr served as the chief executive officer of Surgical Specialties, Inc., a manufacturer of surgical instruments. From May 2012 through August 2013, Mr. Barr served as the President, Global Surgical at Bausch & Lomb Holdings Incorporated, an eye health products company. Mr. Barr previously served on the Board of Directors of Valeritas Holdings Inc., a medical technology company focused on the treatment of diabetes. Mr. Barr holds a B.S. in Bioengineering from the University of Pennsylvania and an M.B.A. from Northwestern University.
John Barr is 62, he's been the Independent Director of Apollo Endosurgery Inc since 2019. There are 5 older and 12 younger executives at Apollo Endosurgery Inc. The oldest executive at Apollo Endosurgery Inc is Dr. Christopher J. Gostout, 70, who is the Co-Founder & Chief Medical Officer.
John's mailing address filed with the SEC is 1120 S CAPITAL OF TX HWY, BLDG 1,STE 300, AUSTIN, TX, 78746.
Over the last 12 years, insiders at Apollo Endosurgery Inc have traded over $3,882,241 worth of Apollo Endosurgery Inc stock and bought 10,717,094 units worth $45,588,363 . The most active insiders traders include Holdings A/S Novo, Neil Gagnon a R Kent Jr Mc Gaughy. On average, Apollo Endosurgery Inc executives and independent directors trade stock every 41 days with the average trade being worth of $2,726,880. The most recent stock trade was executed by Jeffrey G. Black on 25 February 2022, trading 40,000 units of APEN stock currently worth $229,200.
Apollo Endosurgery, Inc. is a medical technology company focused on less invasive therapies to treat various gastrointestinal conditions, ranging from gastrointestinal defect repairs to the interventional treatment of obesity. Apollo's device-based therapies are an alternative to invasive surgical procedures, thus lowering complication rates and reducing total healthcare costs. Apollo's products are offered in over 75 countries today and include the X-Tack™ Endoscopic HeliX Tacking System, the OverStitch™ Endoscopic Suturing System, the OverStitch Sx™ Endoscopic Suturing System, and the ORBERA® Intragastric Balloon.
Apollo Endosurgery Inc executives and other stock owners filed with the SEC include: